Drug Trial Radar · NCT06982651
A Study on the Safety, Pharmacokinetics, and Food Effects of MI078 Capsules
Last checked: Nov 19, 2026Latest source record: May 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
98
Actual
Start
Sep 9, 2023
Primary completion
Mar 18, 2024
Study completion Mar 18, 2024
Sponsor
- Lead sponsor
- Nanjing Minova Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 21, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study was divided into three studies, namely, a single administration study, a food impact study, and a multiple administration study.
Conditions
- Postpartum Depression
Interventions
MI078Drug
Dosage Form: Capsule Specification: 25 mg Administration and Dosage: Oral. 1 capsule per dose, once daily. Duration of Treatment: 1 day Dosage Form: Capsule Specification: 50 mg Administration and Dosage: Oral. 1 capsule per dose, once daily. Duration of Treatment: 1 day Dosage Form: Capsule Specification: 200 mg Administration and Dosage: Oral. Options include: * 1 capsule per dose, once daily; * 2 capsules per dose, once daily; * 3 capsules per dose, once daily; * 4 capsules per dose, once daily; Duration of Treatment: 1 day . Dosage Form: Capsule Specification: 200 mg Administration and Dosage: Oral. Options include: * 1 capsule per dose, twice daily; * 2 capsules per dose, twice daily; Duration of Treatment: 7 days . Dosage Form: Capsule Specification: 50mg Administration and Dosage: Oral. Options include: \- 5 capsule per dose, Three times a day Duration of Treatment: 3 days .
PlaceboDrug
Placebo of MI078 Capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence, severity, and causality of AEs, SAEsTime frame: up to 72 hours after the last dose
- vital signsTime frame: up to 72 hours after the last dose
- SpO₂Time frame: up to 72 hours after the last dose
- 12-lead electrocardiogram (ECG)Time frame: up to 72 hours after the last dose
- Modified Observer's Assessment of Alertness and Sedation Scale(MOAA/S)Time frame: up to 72 hours after the last dose
- Stanford Sleepiness Scale (SSS)Time frame: up to 72 hours after the last dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Third Xiangya Hospital, Central South University
Changsha, Hunan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.